公开(公告)号：WO2019050460A1

公开(公告)日：2019-03-14

申请号：PCT/SE2018/050898

申请日：2018-09-07

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars

IPC: A61K31/737 ,  C08B37/02 ,  A61P25/28

Abstract: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons. The cell differentiation induction of dextran sulfate has positive effects in subjects suffering from neurological diseases,including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.

公开(公告)号：WO2016076780A1

公开(公告)日：2016-05-19

申请号：PCT/SE2015/051188

申请日：2015-11-10

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars ,  BRASEN, Ulf

IPC: A61K31/737 ,  C08B37/02 ,  A61P7/02

CPC classification number: C08L5/02 ,  C08B37/0021 ,  C08L2203/02

Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90 %. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.

Abstract translation: 硫酸葡聚糖或其盐具有在1850和3500Da的间隔内通过NMR光谱测量的数均分子量（Mn）。 硫酸葡聚糖或其盐在2.5和3.0的间隔内也具有每个葡萄糖单元的平均硫酸根数。 此外，硫酸葡聚糖或其盐的葡萄糖单元中C2位置的平均硫酸化为至少90％。 与市售的类似的硫酸葡聚糖分子相比，硫酸葡聚糖具有改善的生物效应和/或降低的毒性。

公开(公告)号：WO2022075913A1

公开(公告)日：2022-04-14

申请号：PCT/SE2021/050983

申请日：2021-10-07

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars

IPC: A61K31/737 ,  A61K31/721 ,  A61P21/00 ,  A61P25/18

Abstract: The present invention relates to the use of dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment or prevention of muscle atrophy in a subject suffering from sarcopenia and in improving muscle function in a subject suffering from a neuromuscular disease and/or damage or sarcopenia.

公开(公告)号：WO2021211044A1

公开(公告)日：2021-10-21

申请号：PCT/SE2021/050345

申请日：2021-04-14

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars

IPC: A61K31/737 ,  A61P7/02 ,  A61P7/04

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment of sepsis and hypercytokinemia.

公开(公告)号：WO2021211043A1

公开(公告)日：2021-10-21

申请号：PCT/SE2021/050344

申请日：2021-04-14

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars

IPC: A61K31/737 ,  A61P31/12

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treatment of a coronavirus infection or infectious disease and infections caused by other HSPG binding pathogens. The invention also relates to treatment of inflammatory diseases, such as ARDS and SIRS, which may occur in connection with such infections.

公开(公告)号：WO2020180238A1

公开(公告)日：2020-09-10

申请号：PCT/SE2020/050245

申请日：2020-03-05

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars

IPC: G01N33/53 ,  G01N33/15 ,  A61K31/37 ,  A61P25/00 ,  G01N33/68

Abstract: The efficiency of dextran sulfate treatment is determined based on differences between the amount of biomarkers determined in a second biological sample taken from the patient following dextran sulfate administration and in a first biological sample taken from the patient prior to dextran sulfate administration.The biomarkers are selected from 6 groups consisting of PFA4and VAV3 (group 1); TNFSF15, IL-17B, TSLP and CRH(group 2); FGF1 and KITLG (group 3);BDNF, NOG and HBEGF (group 4);AFP,ATP2A3, SLC29A1,SLC40A1 and TTR(group 5);and SLC1A4, SLC7A11, SLC16A7, LDLR and ATP8A1(group 6).

公开(公告)号：WO2015190989A1

公开(公告)日：2015-12-17

申请号：PCT/SE2015/050677

申请日：2015-06-11

Applicant: TX MEDIC AB

Inventor： WAAS, Anders ,  BRUCE, Lars ,  BRUCE, Adam

IPC: A61K31/721 ,  A61P9/10

CPC classification number: A61K31/721 ,  A61K9/0019

Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Abstract translation: 本实施方案涉及平均分子量低于10000Da的硫酸葡聚糖在受试者中诱导血管生成并增加患有缺血的受试者的血液流动的用途。

公开(公告)号：WO2022071841A1

公开(公告)日：2022-04-07

申请号：PCT/SE2021/050895

申请日：2021-09-17

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars ,  BRUCE, Adam

IPC: A61P1/16 ,  A61K31/737 ,  C08B37/02 ,  C08L5/02

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in improving liver function in a subject suffering from a non-alcoholic fatty liver disease (NAFLD). The dextran sulfate, or the pharmaceutically acceptable salt thereof, has an average molecular weight equal to or below 10 000 Da and is formulated for intravenous or subcutaneous administration to the subject.

公开(公告)号：WO2018212708A1

公开(公告)日：2018-11-22

申请号：PCT/SE2018/050506

申请日：2018-05-16

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars ,  BRUCE, Adam

IPC: A61K31/721 ,  A61K9/00 ,  A61P27/06

Abstract: The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.

公开(公告)号：WO2017018922A1

公开(公告)日：2017-02-02

申请号：PCT/SE2016/050720

申请日：2016-07-15

Applicant: TX MEDIC AB

Inventor： BRUCE, Lars ,  BRUCE, Adam ,  WAAS, Anders

IPC: A61K31/721 ,  A61P9/10 ,  C08B37/02 ,  C08L5/02

CPC classification number: A61K31/737 ,  A61P9/10

Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.

Abstract translation: 本实施方案涉及配制用于全身给药的硫酸葡聚糖用于治疗，抑制或预防受试者心脏纤维化的用途。